Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

bi-sialidase fusion protein E-602

A fusion protein composed of two engineered human sialidase molecules fused to an Fc antibody domain, with potential immunomodulating and antineoplastic activities. Upon administration, bi-sialidase fusion protein E-602 targets and binds to sialoglycans overexpressed on the cell surface of certain tumor cells and immune cells, such as exhausted T cells. This degrades the immunosuppressive sialoglycans and allows for the re-activation of the immune system, thereby inducing an anti-tumor immune response. Sialidase is an enzymatic degrader of immunosuppressive sialoglycans. E-602 is based on the enzyme-antibody glyco-ligand editing (EAGLE) platform. The Fc domain enhances retention in the tumor, half-life and manufacturability.
Synonym:EAGLE fusion protein E-602
Code name:E 602
E-602
E602
Search NCI's Drug Dictionary